This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Trial Comparing the Safety of Two Different Intravenous Iron Formulations

This study has suspended participant recruitment.
(Interim Analysis and review by Data Safety Monitoring Board)
Information provided by:
London Health Sciences Centre Identifier:
First received: January 3, 2008
Last updated: March 2, 2009
Last verified: February 2009
The purpose of this trial is to compare the safety profile using equal doses of intravenous iron dextran versus iron sucrose. The researchers hypothesize that significantly more patients receiving intravenous iron dextran (using the current intermediate molecular weight product) will have severe adverse outcomes than patients receiving iron sucrose in the adult non-hemodialysis outpatient population. Secondly, since these severe reactions may require additional nursing time and physician interventions that may negate any cost advantage of iron dextran, the researchers hypothesize that iron sucrose will be more cost-effective than iron dextran.

Condition Intervention Phase
Iron Deficiency Anemia Perioperative Blood Conservation Drug: Iron dextran Drug: Iron sucrose Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Randomized Double-Blind Safety Comparison of Intravenous Iron Dextran Versus Iron Sucrose in an Adult Non-Hemodialysis Outpatient Population: A Pilot Study

Resource links provided by NLM:

Further study details as provided by London Health Sciences Centre:

Primary Outcome Measures:
  • Incidence of severe adverse drug reactions (ADRs) [ Time Frame: Immediate - during infusion ]

Secondary Outcome Measures:
  • Incidence of serious adverse drug reactions (ADRs) [ Time Frame: Immediate and delayed - within 24hrs post infusion ]
  • Incidence of anaphylactic/anaphylactoid ADRs [ Time Frame: Immediate - during infusion ]
  • Incidence of combined mild and moderate ADRs [ Time Frame: Immediate - during infusion ]
  • Incidence of delayed ADRs [ Time Frame: delayed - within 24hrs post infusion ]
  • Incidence of all-cause mortality [ Time Frame: Immediate and delayed - within 24hrs post infusion ]
  • Physician and nursing time required to manage ADRs [ Time Frame: Immediate and delayed - within 24hrs post infusion ]
  • Response in laboratory parameters [ Time Frame: Within 1 month ]
  • Cost effectiveness [ Time Frame: Completion of study ]

Estimated Enrollment: 200
Study Start Date: January 2008
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Iron Dextran Drug: Iron dextran
300mg in 250cc normal saline given over 2 hours
Other Name: Infufer, Sandoz Canada Incorporated, DIN 02221780
Active Comparator: Iron Sucrose Drug: Iron sucrose
300mg in 250cc normal saline given over 2 hours
Other Name: Venofer, Luitpold Pharmaceuticals Inc., DIN 02243716


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 to 100
  • To be receiving intravenous iron

Exclusion Criteria:

  • Age < 18
  • Hemodialysis
  • Previous exposure to intravenous iron
  • Unable to provide written consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00593619

Canada, Ontario
London Health Sciences Centre
London, Ontario, Canada, N6A 5W9
Sponsors and Collaborators
London Health Sciences Centre
Principal Investigator: Ian H Chin-Yee, MD, FRCPC London Health Sciences Centre
Principal Investigator: Fiona E Ralley, MB ChB, FRCA London Health Sciences Centre
Study Director: Cyrus C Hsia, MD,FRCPC London Health Sciences Centre
  More Information

Responsible Party: Ian H. Chin-Yee, Chair/Chief of Hematology, London Health Sciences Centre Identifier: NCT00593619     History of Changes
Other Study ID Numbers: HSREB13767
Study First Received: January 3, 2008
Last Updated: March 2, 2009

Keywords provided by London Health Sciences Centre:
Intravenous Iron
Iron deficiency
Non hemodialysis population
Perioperative blood conservation

Additional relevant MeSH terms:
Anemia, Iron-Deficiency
Anemia, Hypochromic
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Ferric oxide, saccharated
Ferric Compounds
Iron-Dextran Complex
Trace Elements
Growth Substances
Physiological Effects of Drugs
Plasma Substitutes
Blood Substitutes processed this record on September 19, 2017